{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:22:55Z","timestamp":1747171375192,"version":"3.40.5"},"reference-count":108,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.tcm.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T17:26:18Z","timestamp":1522862778000},"page":"469-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options"],"prefix":"10.1016","volume":"28","author":[{"given":"Jonathan","family":"Stock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-9465","authenticated-orcid":false,"given":"Brian J.","family":"Malm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.tcm.2018.03.004_bib0001","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.tcm.2018.03.004_bib0002","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.tcm.2018.03.004_bib0003","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"issue":"22","key":"10.1016\/j.tcm.2018.03.004_bib0004","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.tcm.2018.03.004_bib0005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2007.09.065","article-title":"Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation","volume":"51","author":"Fang","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.tcm.2018.03.004_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.tcm.2018.03.004_bib0007","series-title":"(2013, September 1) Presented at the European Society of Cardiology (ESC) Congress","article-title":"German Competence Network on Atrial Fibrillation (AFNET). CHADS2 risk score assigns over one-third of stroke patients to low or intermediate stroke risk","author":"Nabauer","year":"2013"},{"issue":"21","key":"10.1016\/j.tcm.2018.03.004_bib0008","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.tcm.2018.03.004_bib0009","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0735-1097(98)00146-6","article-title":"Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation","volume":"31","author":"Zabalgoitia","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.tcm.2018.03.004_bib0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.4065\/83.10.1107","article-title":"Increased left atrial volume index: potent biomarker for first-ever ischemic stroke","volume":"83","author":"Fatema","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tcm.2018.03.004_bib0011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/CIRCULATIONAHA.113.006286","article-title":"ARISTOTLE investigators. high-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2018.03.004_bib0012","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jacc.2013.07.093","article-title":"ARISTOTLE investigators. high-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin","volume":"63","author":"Hijazi","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0013","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jacc.2012.11.082","article-title":"N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (apixaban for the prevention of stroke in subjects with atrial fibrillation)","volume":"61","author":"Hijazi","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.tcm.2018.03.004_bib0014","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2018.03.004_bib0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.thromres.2004.11.025","article-title":"Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal","volume":"117","author":"Od\u00e9n","year":"2006","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.tcm.2018.03.004_bib0017","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1378\/chest.126.6.1938","article-title":"Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis","volume":"126","author":"Reynolds","year":"2004","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.tcm.2018.03.004_bib0018","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jacc.2007.07.076","article-title":"Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy","volume":"50","author":"Hohnloser","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.tcm.2018.03.004_bib0019","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","author":"Go","year":"2003","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.tcm.2018.03.004_bib0020","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","volume":"57","author":"Fuster","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.tcm.2018.03.004_bib0021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjmed.2010.05.007","article-title":"Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation","volume":"124","author":"Lip","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0022","doi-asserted-by":"crossref","unstructured":"Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Jun;164(12):826\u2013835.","DOI":"10.7326\/M15-2112"},{"issue":"25","key":"10.1016\/j.tcm.2018.03.004_bib0023","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.jacc.2016.03.581","article-title":"Aspirin instead of oral anticoagulation prescription in atrial fibrillation patients at risk for stroke","volume":"67","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0024","doi-asserted-by":"crossref","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","article-title":"Warfarin Use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"131","author":"Go","year":"1999","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.tcm.2018.03.004_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgs.14688","article-title":"Use of oral anticoagulant therapy in older adults with atrial fibrillation after acute ischemic stroke","volume":"65","author":"McGrath","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.tcm.2018.03.004_bib0026","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.amjcard.2005.09.086","article-title":"Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry","volume":"97","author":"Reynolds","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0027","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"DG1","year":"2002","journal-title":"N Engl J Med"},{"issue":"9028","key":"10.1016\/j.tcm.2018.03.004_bib0028","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"9526","key":"10.1016\/j.tcm.2018.03.004_bib0029","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial","volume":"367","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2018.03.004_bib0030","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.tcm.2018.03.004_bib0031","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.tcm.2018.03.004_bib0032","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.2146\/ajhp100348","article-title":"Dabigatran etexilate: a novel oral direct thrombin inhibitor","volume":"68","author":"Blommel","year":"2011","journal-title":"Am J Health\u2013Syst Pharm"},{"issue":"2","key":"10.1016\/j.tcm.2018.03.004_bib0033","first-page":"223","article-title":"ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"57","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"2 Suppl","key":"10.1016\/j.tcm.2018.03.004_bib0034","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.tcm.2018.03.004_bib0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0036","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.tcm.2018.03.004_bib0037","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","article-title":"Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial","volume":"34","author":"Al-Khatib","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2018.03.004_bib0038","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0039","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCOUTCOMES.112.965988","article-title":"Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation","volume":"5","author":"Schneeweiss","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"15","key":"10.1016\/j.tcm.2018.03.004_bib0041","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2014.07.967","article-title":"Amiodarone, anticoagulation and clinical events in patients with atrial fibrillation","volume":"64","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.tcm.2018.03.004_bib0042","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation","volume":"44","author":"Harrington","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.tcm.2018.03.004_bib0043","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.tcm.2018.03.004_bib0044","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tcm.2018.03.004_bib0045","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"issue":"9921","key":"10.1016\/j.tcm.2018.03.004_bib0046","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.tcm.2018.03.004_bib0047","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"Gomez-Outes","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.tcm.2018.03.004_bib0048","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.tcm.2018.03.004_bib0049","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.tcm.2018.03.004_bib0050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"Friberg","year":"2015","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.tcm.2018.03.004_bib0051","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacc.2014.11.013","article-title":"Adding rigor to stroke risk prediction in atrial fibrillation","volume":"65","author":"Singer","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.tcm.2018.03.004_bib0052","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Aalvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"69","author":"Caterina","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.tcm.2018.03.004_bib0053","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0054","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0055","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u201cvalvular\u201d atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2018.03.004_bib0056","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.tcm.2018.03.004_bib0057","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/archinte.165.13.1527","article-title":"Risks of oral anticoagulant therapy with increasing age","volume":"165","author":"Torn","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0058","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archinte.163.13.1580","article-title":"Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded","volume":"163","author":"Man-Son-Hing","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0059","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1001\/archinte.1991.00400100038006","article-title":"Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation","volume":"151","author":"Kutner","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2018.03.004_bib0061","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.amjmed.2005.02.022","article-title":"Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall","volume":"118","author":"Gage","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0062","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archinte.159.7.677","article-title":"Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls","volume":"159","author":"Man-Son-Hing","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0063","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ahj.2010.11.002","article-title":"Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients","volume":"161","author":"Sellers","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.tcm.2018.03.004_bib0064","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2018.03.004_bib0065","doi-asserted-by":"crossref","first-page":"A148","DOI":"10.1161\/str.43.suppl_1.A148","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular AF in the ROCKET-AF trial","volume":"43","author":"Halperin","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.tcm.2018.03.004_bib0066","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2010.05.023","article-title":"Warfarin dosing in patients with impaired kidney function","volume":"56","author":"Limdi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.tcm.2018.03.004_bib0067","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","article-title":"Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0068","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.115.018294","article-title":"Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation","volume":"133","author":"Shih","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2018.03.004_bib0069","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.113.004777","article-title":"Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis","volume":"129","author":"Shah","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.tcm.2018.03.004_bib0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2015.05.019","article-title":"Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation","volume":"66","author":"Shen","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"10.1016\/j.tcm.2018.03.004_bib0071","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0072","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/CIRCULATIONAHA.113.007549","article-title":"A pint of sweat will save a gallon of blood: a call for randomized trials of anticoagulation in end-stage renal disease","volume":"129","author":"Granger","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2018.03.004_bib0073","doi-asserted-by":"crossref","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2018.03.004_bib0074","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study","volume":"271","author":"Emelia","year":"1994","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.tcm.2018.03.004_bib0075","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0076","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.177031","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the management of patients with atrial fibrillation\u2014executive summary","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.tcm.2018.03.004_bib0077","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/eurheartj\/ehl488","article-title":"Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting","volume":"28","author":"Karjalainen","year":"2007","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.tcm.2018.03.004_bib0078","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ahj.2003.06.004","article-title":"Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation","volume":"147","author":"Orford","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.tcm.2018.03.004_bib0079","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"issue":"9872","key":"10.1016\/j.tcm.2018.03.004_bib0080","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.tcm.2018.03.004_bib0081","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.tcm.2018.03.004_bib0082","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.tcm.2018.03.004_bib0083","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI: the PIONEER AF-PCI trial","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.tcm.2018.03.004_bib0084","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2018.03.004_bib0085","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"4 Suppl S","key":"10.1016\/j.tcm.2018.03.004_bib0086","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/S0735-1097(02)02776-6","article-title":"Oral anticoagulants in patients with coronary artery disease","volume":"41","author":"Anand","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0087","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","article-title":"AHA\/ACCF Secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"58","author":"Smith","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.tcm.2018.03.004_bib0088","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients on oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2018.03.004_bib0089","unstructured":"Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01962545."},{"key":"10.1016\/j.tcm.2018.03.004_bib0090","unstructured":"Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02024230."},{"issue":"12","key":"10.1016\/j.tcm.2018.03.004_bib0091","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jacep.2017.04.024","article-title":"Patients with atrial fibrillation who are not on anticoagulant treatment due to increased bleeding risk are common and have a high risk of stroke","volume":"3","author":"Redfors","year":"2017","journal-title":"JACCClin Electrophysiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0092","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with AF","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"10.1016\/j.tcm.2018.03.004_bib0093","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4244\/EIJY15M01_06","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug","volume":"11","author":"Tzikas","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.tcm.2018.03.004_bib0094","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tcm.2018.03.004_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the prevail trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2018.03.004_bib0096","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.hrthm.2016.01.022","article-title":"Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation","volume":"13","author":"Lakkireddy","year":"2016","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.tcm.2018.03.004_bib0097","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0735-1097(00)00765-8","article-title":"Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study","volume":"36","author":"Katz","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.tcm.2018.03.004_bib0098","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0735-1097(03)00954-9","article-title":"Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study","volume":"42","author":"Garc\u00eda-Fern\u00e1ndez","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"October (38)","key":"10.1016\/j.tcm.2018.03.004_bib0099","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.tcm.2018.03.004_bib0100","doi-asserted-by":"crossref","unstructured":"Inoue H. Thromboembolism in patients with nonvalvular atrial fibrillation: comparison between Asian and Western countries. J Cardiol. 2013 January;61(1):1\u20137.","DOI":"10.1016\/j.jjcc.2012.08.012"},{"key":"10.1016\/j.tcm.2018.03.004_bib0101","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"Cryptogenic stroke and atrial fibrillation","volume":"370","author":"Gladstone","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.tcm.2018.03.004_bib0102","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.0b013e31828f1828","article-title":"Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke","volume":"80","author":"Cotter","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tcm.2018.03.004_bib0103","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jce.12842","article-title":"PULSE-SMART: pulse-based arrhythmia discrimination using a novel smartphone application","volume":"27","author":"McManus","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"October(10)","key":"10.1016\/j.tcm.2018.03.004_bib0104","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm."},{"issue":"April (17)","key":"10.1016\/j.tcm.2018.03.004_bib0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N Engl J Med"},{"issue":"July (28)","key":"10.1016\/j.tcm.2018.03.004_bib0106","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"issue":"August (8)","key":"10.1016\/j.tcm.2018.03.004_bib0107","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.106.641225","article-title":"Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation","volume":"114","author":"Oral","year":"2006","journal-title":"Circulation"},{"issue":"November (11)","key":"10.1016\/j.tcm.2018.03.004_bib0108","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/europace\/euw343","article-title":"Incidence of new-onset atrial fibrillation after cavotricuspid isthmus ablation for atrial flutter","volume":"19","author":"Celikyurt","year":"2017","journal-title":"Europace"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173818300471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173818300471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T02:04:24Z","timestamp":1660788264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173818300471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1050173818300471"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2018.03.004","relation":{},"ISSN":["1050-1738"],"issn-type":[{"type":"print","value":"1050-1738"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}